FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to clinical laboratory diagnostics, microbiology, pulmonology, and can be used to assess the risk of developing complications of an infectious process in patients with cystic fibrosis. The method is implemented in that, in contrast to the known methods for assessing the risk of complications of an infectious process in patients with cystic fibrosis, sputum from patients with cystic fibrosis is collected in a sterile disposable container, centrifuged at 1700 G for 5 minutes, the resulting supernatant is re-centrifuged at 4500 G for 5 minutes. within 5 minutes. After that, the concentration of ferritin is determined on an automatic biochemical analyzer using the immunoturbodimetric method, characterized in that the study is carried out in dynamics with the calculation of the PCV coefficient: if the patient is not exacerbated, then the PCV coefficient is calculated between two consecutive determinations of ferritin in sputum with an interval of 1 time per 3 months, with a PCV value <37.3%, the risk of an exacerbation of the infectious process is low; during an exacerbation, the PCV coefficient is calculated between the last ferritin value determined outside the exacerbation and the ferritin value determined during the exacerbation, a PCV value from 37.3% to 45.7% inclusive corresponds to an exacerbation without seeding microorganisms from the Burkholderia cepacia complex; a value from 45.8% to 78.3% inclusive corresponds to an exacerbation with the inoculation of microorganisms from the Burkholderia cepacia complex; an increase in the PCV value above 78.4% corresponds to the "cepation syndrome".
EFFECT: invention provides an assessment of the risk of complications of the infectious process in patients with cystic fibrosis according to the Personal Change Value (PCV) coefficient for ferritin in sputum.
1 cl, 2 dwg, 4 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR ASSESSING ACTIVITY OF INFECTIOUS PROCESS CAUSED BY NON-FERMENTATIVE GRAM-NEGATIVE BACTERIA IN BRONCHOPULMONARY SYSTEM IN PATIENTS WITH CYSTIC FIBROSIS | 2018 |
|
RU2686052C1 |
NUTRIENT MEDIUM FOR CULTIVATING MICROORGANISMS FROM BURKHOLDERIA CEPACIA COMPLEX | 2021 |
|
RU2759831C1 |
METHOD FOR PRIMARY SEEDING OF BIOMATERIAL ISOLATED FROM THE ORAL CAVITY OF PATIENTS WITH CYSTIC FIBRIOSIS DURING DENTAL EXAMINATION | 2022 |
|
RU2779641C1 |
METHOD FOR COLLECTING BIOMATERIAL FOR MICROBIOLOGICAL RESEARCH DURING DENTAL EXAMINATION OF PATIENTS WITH CYSTIC FIBRIOSIS | 2022 |
|
RU2779689C1 |
METHOD OF PRIMARY SOWING OF BIOMATERIAL, DIVIDED FROM THE LOWER RESPIRATORY WAYS OF PATIENTS WITH CYSTIC FIBROSIS | 2017 |
|
RU2668406C1 |
METHOD FOR PRIMARY PLATING OF PERIODONTAL POCKETS | 2022 |
|
RU2794355C1 |
USING LEVOFLOXACIN IN AEROSOL FORM FOR TREATING MUCOVISCIDOSIS | 2010 |
|
RU2563809C2 |
METHOD FOR PREDICTING THE RISK OF EXACERBATION OF CHRONIC GINGIVITIS IN PATIENTS WITH A NEW CORONAVIRUS INFECTION | 2022 |
|
RU2784295C1 |
METHOD FOR PRIMARY SOWING OF CLINICAL MATERIAL FOR ISOLATING NON-TUBERCULOSIS MICOBACTERIA | 2019 |
|
RU2711957C1 |
METHOD FOR CORRECTION OF COMPOSITION OF INTESTINAL MICROFLORA IN CHILDREN | 2022 |
|
RU2801611C1 |
Authors
Dates
2023-01-30—Published
2022-08-16—Filed